Somewhat Positive Press Coverage Somewhat Unlikely to Impact Amedisys (AMED) Stock Price

Media headlines about Amedisys (NASDAQ:AMED) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amedisys earned a news impact score of 0.23 on Accern’s scale. Accern also gave news articles about the health services provider an impact score of 46.3981146760992 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the headlines that may have impacted Accern’s scoring:

Shares of Amedisys (AMED) traded down $0.25 on Friday, hitting $56.12. The company’s stock had a trading volume of 243,275 shares, compared to its average volume of 502,491. Amedisys has a twelve month low of $38.00 and a twelve month high of $65.91. The firm has a market cap of $1,904.54, a P/E ratio of 26.85, a PEG ratio of 1.36 and a beta of 0.68. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.

Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to the consensus estimate of $384.59 million. Amedisys had a return on equity of 14.68% and a net margin of 2.88%. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period last year, the company earned $0.36 EPS. equities analysts expect that Amedisys will post 2.23 EPS for the current year.

Several brokerages have recently weighed in on AMED. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $60.00 target price on shares of Amedisys in a research note on Friday, September 15th. BidaskClub downgraded Amedisys from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Mizuho reaffirmed a “buy” rating and set a $65.00 target price (up from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Bank of America Corporation began coverage on Amedisys in a research note on Monday, August 21st. They set a “neutral” rating and a $55.00 target price for the company. Finally, Royal Bank Of Canada reissued a “hold” rating on shares of Amedisys in a research note on Monday, October 23rd. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $61.00.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://transcriptdaily.com/2017/11/27/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-amedisys-amed-stock-price.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply